Drug level treated with 5-((R)-4-((R)-3-Methylmorpholino)-5a,6,8,9-tetrahydro-5H-pyrimido[5',4':4,5]pyrrolo[2,1-c][1,4]oxazin-2-yl)pyrimidin-2-amine assessed as recombinant human CYP1A1-mediated compound formation incubated for 60 mins by LC/MS analysis
Drug level treated with 5-((R)-4-((R)-3-Methylmorpholino)-5a,6,8,9-tetrahydro-5H-pyrimido[5',4':4,5]pyrrolo[2,1-c][1,4]oxazin-2-yl)pyrimidin-2-amine assessed as recombinant human CYP1A2-mediated compound formation incubated for 60 mins by LC/MS analysis